Camp4 gains after earning bullish views on Street
Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...
Fintel on MSN1d
Leerink Partners Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation
Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...
Camp4 Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...
Business Insider2d
Camp4 Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $23 price target The firm says its bullish thesis is based on Camp4’s ASO RNA Actuator Platform ...
The Business Journals24d
Camp4 CEO credits CFO, investors' 'risk appetite’ for IPO
Camp4 Therapeutics CEO Josh Mandel-Brehm said the biotech's IPO shows a changing environment. After Camp4 Therapeutics Inc. made its Nasdaq debut on Friday, founding CEO Josh Mandel-Brehm said the ...
The Motley Fool2d
Camp4 Therapeutics (NASDAQ: CAMP)
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...
Seeking Alpha28d
CAMP4 Therapeutics Readies $75 Million IPO Plan
CAMP4 Therapeutics (CAMP) has filed proposed terms to raise $75 million from the sale of its common stock in an IPO, according to an amended SEC registration statement. The firm is a clinical ...
Morningstar6d
Camp4 Therapeutics Corp CAMP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Investing2d
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology
On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...
Investing2d
Leerink sets stock target for CAMP4, cites broad UCD treatment potential
Tuesday, Leerink Partners initiated coverage on shares of CAMP4 Therapeutics Corp (NASDAQ: CAMP) with an Outperform rating and a price target of $17.00. The coverage is based on the potential of the ...
Morningstar6d
Camp4 Therapeutics Corp
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...